Other examples identified in our analysis include tocilizumab and sarilumab which target the IL6R and found to reduce the need for mechanical ventilation and the length of hospital stay59, the anti-IL6 antibody siltuximab which has been recently shown to improve survival in hospitalized COVID-19 patients60, and the JAK inhibitor ruxolitinib which has been shown to reduce the risk of mechanical ventilation and its duration59. This evidence concerns the gene IL6R and COVID-19.